Guest Editors:
Franco Muggia, New York University Langone Medical Center, New York, USA
Eleonora Teplinsky, New York University Langone Medical Center, New York, USA
Epithelial ovarian cancer and related cancers arising in extrauterine Mullerian epithelium are generally chemosensitive, particularly to the platinum drugs cisplatin and carboplatin that form the backbone of first-line treatments upon diagnosis even at early stages. Doublets of platinums with paclitaxel have represented the standard-of-care since the late 1990s, with further notable advances taking place by intraperitoneal administration (in Gynecologic Oncology Group studies) after optimal surgical cytoreduction is achieved, and by divided doses of paclitaxel (in a Japanese GOG study).
Adding another agent to improve on these results has otherwise proven to be quite challenging. Nevertheless, continued forays into introducing ‘targeted therapies’ are beginning to bear fruit and form part of this focused issue. The purpose of this issue is to provide a glimpse of where the field is moving, and their successes to date.
